Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-5475 · 1 trial · 1 indication
Amount of \[14C\]MK-5475 and its metabolites excreted in urine (Aeu) derived from urine collections at each sampling interval.
Cumulative amount of \[14C\] MK-5475 and its metabolites excreted in urine derived from urine collections at each sampling interval
Percentage of \[14C\]MK-5475 and its metabolites excreted in urine derived from urine collections at each sampling interval.
Cumulative percentage of \[14C\]MK-5475 and its metabolites excreted in urine derived from urine collections at each sampling interval.
Amount of \[14C\]MK-5475 and its metabolites excreted in feces derived from feces collections at each sampling interval.
Cumulative amount of \[14C\]MK-5475 and its metabolites excreted in feces derived from feces collections at each sampling interval.
Cumulative percentage of \[14C\]MK-5475 and its metabolites excreted in feces derived from feces collections at each sampling interval.
Area under concentration time curve (AUC) from time zero to the last quantifiable concentration derived from the whole blood and plasma concentration-time profiles following IV administration of \[14C\]MK-5475.
AUC from time zero extrapolated to infinity derived from the whole blood and plasma concentration-time profiles following IV administration of \[14C\]MK-5475.
Cmax is the measure of the maximum amount of \[14C\]MK-5475 in the plasma after the dose is given.
T1/2 is the time required for \[14C\]MK-5475 concentration in the plasma to decrease by 50%.
Tmax is a measure of the time to reach the maximum concentration in the plasma after the \[14C\]MK-5475 dose.
CL is defined as apparent total clearance of \[14C\]MK-5475 from plasma after IV administration
Vz is defined as apparent volume of distribution of \[14C\]MK-5475 during terminal phase after IV administration.
AUC time zero to infinity (0-∞) of \[14C\]MK-5475 in plasma/AUC0-∞ of total radioactivity in plasma.
| Arm | Type | Description |
|---|---|---|
| [14C] MK-5475 | EXPERIMENTAL | \[14C\] MK-5475 is administered as single IV bolus dose of 100μg on Day 1. |
| Name | Type | Description |
|---|---|---|
| [14C] MK-5475 | DRUG | \[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1. |
Inclusion Criteria: * Is in good health. * Body mass index (BMI) \>18 and ≤32 kg/m2, inclusive. Exclusion Criteria: * Has history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological ...
MK-5475 is an investigational small molecule being developed by Merck & Company, Inc. (MRK). It is currently in Phase 1 clinical development. The drug is being studied in healthy participants to understand how it is taken up by the body, broken down, and removed.
MK-5475 is being studied in healthy participants as part of a Phase 1 clinical trial. The study is designed to understand how the radiolabeled form of the drug is absorbed, metabolized, and excreted from the body. It is not yet approved for any medical condition.
MK-5475 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial to evaluate the drug's absorption, metabolism, and elimination in healthy male participants.
MK-5475 is in Phase 1 clinical development. The single completed trial, NCT06777602, enrolled 8 healthy male participants in the United States. The drug is investigational and has not been approved by regulatory authorities.
MK-5475 has one completed Phase 1 clinical trial, NCT06777602, titled "A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)." The trial enrolled 8 healthy male participants aged 18 years and older in the United States.